421 related articles for article (PubMed ID: 23868905)
21. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
Cortés J; Swain SM; Kudaba I; Hauschild M; Patel T; Grincuka E; Masuda N; McNally V; Ross G; Brewster M; Marier JF; Trinh MM; Garg A; Nijem I; Visich J; Lum BL; Baselga J
Anticancer Drugs; 2013 Nov; 24(10):1084-92. PubMed ID: 23969513
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
23. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
Xu B; Li W; Zhang Q; Li Q; Wang X; Li H; Sun T; Yin Y; Zheng H; Feng J; Zhu H; Siddiqui A; Macharia H; Knott A
Breast Cancer Res Treat; 2023 Feb; 197(3):503-513. PubMed ID: 36463547
[TBL] [Abstract][Full Text] [Related]
24. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
Fleeman N; Bagust A; Beale S; Dwan K; Dickson R; Proudlove C; Dundar Y
Pharmacoeconomics; 2015 Jan; 33(1):13-23. PubMed ID: 25138171
[TBL] [Abstract][Full Text] [Related]
25. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
Tian T; Ye J; Zhou S
Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130
[TBL] [Abstract][Full Text] [Related]
26. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot XB; Burris HA; Petersen JA; De Haas S; Hoersch S; Patre M; Ellis PA
Cancer; 2019 Nov; 125(22):3974-3984. PubMed ID: 31318460
[TBL] [Abstract][Full Text] [Related]
28. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
Shao Z; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang H; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Li J; Zhou J; Althaus B; Mao Y; Eng-Wong J
JAMA Oncol; 2020 Mar; 6(3):e193692. PubMed ID: 31647503
[TBL] [Abstract][Full Text] [Related]
30. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
31. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
Baselga J; Cortés J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM
J Clin Oncol; 2014 Nov; 32(33):3753-61. PubMed ID: 25332247
[TBL] [Abstract][Full Text] [Related]
32. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.
Garg A; Li J; Clark E; Knott A; Carrothers TJ; Marier JF; Cortés J; Brewster M; Visich J; Lum B
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1133-41. PubMed ID: 23999693
[TBL] [Abstract][Full Text] [Related]
33. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
34. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.
De Placido S; Giuliano M; Schettini F; Von Arx C; Buono G; Riccardi F; Cianniello D; Caputo R; Puglisi F; Bonotto M; Fabi A; Bilancia D; Ciccarese M; Lorusso V; Michelotti A; Bruzzese D; Veneziani BM; Locci M; De Laurentiis M; Arpino G
Breast; 2018 Apr; 38():86-91. PubMed ID: 29287189
[TBL] [Abstract][Full Text] [Related]
35. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
Takahashi M; Ohtani S; Nagai SE; Takashima S; Yamaguchi M; Tsuneizumi M; Komoike Y; Osako T; Ito Y; Ikeda M; Ishida K; Nakayama T; Takashima T; Asakawa T; Matsumoto S; Shimizu D; Masuda N
Breast Cancer Res Treat; 2021 Jan; 185(1):125-134. PubMed ID: 32920732
[TBL] [Abstract][Full Text] [Related]
37. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer.
Keating GM
Drugs; 2012 Feb; 72(3):353-60. PubMed ID: 22316351
[TBL] [Abstract][Full Text] [Related]
38. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.
Rimawi M; Ferrero JM; de la Haba-Rodriguez J; Poole C; De Placido S; Osborne CK; Hegg R; Easton V; Wohlfarth C; Arpino G;
J Clin Oncol; 2018 Oct; 36(28):2826-2835. PubMed ID: 30106636
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G; Procter M; de Azambuja E; Zardavas D; Benyunes M; Viale G; Suter T; Arahmani A; Rouchet N; Clark E; Knott A; Lang I; Levy C; Yardley DA; Bines J; Gelber RD; Piccart M; Baselga J;
N Engl J Med; 2017 Jul; 377(2):122-131. PubMed ID: 28581356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
